IO Biotech, Inc.

NasdaqGS:IOBT Stock Report

Market Cap: US$13.9m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

IO Biotech Future Growth

Future criteria checks 0/6

IO Biotech is forecast to grow earnings and revenue by 34.2% and 61.2% per annum respectively. EPS is expected to grow by 42.6% per annum. Return on equity is forecast to be -48.7% in 3 years.

Key information

34.2%

Earnings growth rate

42.61%

EPS growth rate

Biotechs earnings growth28.9%
Revenue growth rate61.2%
Future return on equity-48.73%
Analyst coverage

Low

Last updated20 Feb 2026

Recent future growth updates

Recent updates

Seeking Alpha • Aug 11

IO Biotech's Phase 3 Trial Fails To Deliver

Summary IO Biotech has been anticipating an important phase 3 trial readout for their novel immunotherapy candidate in melanoma. IOBT's topline data showcase "clinically positive," but statistically insignificant results. This article considers the updated investment thesis based on this readout, potential subgroups, and the dwindling cash reserves. Read the full article on Seeking Alpha
Analysis Article • Apr 02

Can IO Biotech (NASDAQ:IOBT) Afford To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analysis Article • Dec 17

Here's Why We're A Bit Worried About IO Biotech's (NASDAQ:IOBT) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analysis Article • Jun 12

We're A Little Worried About IO Biotech's (NASDAQ:IOBT) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Feb 10

We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth Carefully

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Analysis Article • Jun 15

We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth Carefully

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Analysis Article • Jan 20

We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth Carefully

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seeking Alpha • Oct 13

IO Biotech names new CFO

IO Biotech (NASDAQ:IOBT) announced Thursday the appointment of Amy Sullivan as its new chief financial officer.  Sullivan joins IO Biotech from TABA, BV, where she served as chief financial officer. Earlier, Sullivan was chief strategy officer for Euronext-listed Kiadis Pharma where she was responsible for all aspects of fundraising and capital formation strategy.
Analysis Article • Sep 27

We're Keeping An Eye On IO Biotech's (NASDAQ:IOBT) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Aug 11

IO Biotech GAAP EPS of -$0.64

IO Biotech press release (NASDAQ:IOBT): Q2 GAAP EPS of -$0.64. Cash and cash equivalents at June 30, 2022 were $170.1 million, compared to $211.5 million at December 31, 2021. Cash on hand is expected to support operations through anticipated data readouts into mid-2024.
Analysis Article • Jun 14

We're Keeping An Eye On IO Biotech's (NASDAQ:IOBT) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysis Article • Feb 25

We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth Carefully

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Earnings and Revenue Growth Forecasts

NasdaqGS:IOBT - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20287-22-23N/A2
12/31/20271-54-75N/A2
12/31/2026N/A-49-71N/A3
12/31/2025N/A-79-69N/A3
9/30/2025N/A-88-81-81N/A
6/30/2025N/A-104-83-83N/A
3/31/2025N/A-98-81-80N/A
12/31/2024N/A-95-82-82N/A
9/30/2024N/A-90-86-86N/A
6/30/2024N/A-88-81-81N/A
3/31/2024N/A-88-82-82N/A
12/31/2023N/A-86-72-72N/A
9/30/2023N/A-80-62-61N/A
6/30/2023N/A-74-59-59N/A
3/31/2023N/A-71-54-54N/A
12/31/2022N/A-71-60-60N/A
9/30/2022N/A-74-67-66N/A
6/30/2022N/A-65-62-61N/A
3/31/2022N/A-87-58-58N/A
12/31/2021N/A-75-41-41N/A
9/30/2021N/A-56-25-24N/A
6/30/2021N/A-54-18-18N/A
3/31/2021N/A-17-11-11N/A
12/31/2020N/A-15-10-10N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: IOBT is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: IOBT is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: IOBT is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: IOBT is forecast to have no revenue next year.

High Growth Revenue: IOBT is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: IOBT is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/03/30 22:05
End of Day Share Price 2026/03/30 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

IO Biotech, Inc. is covered by 2 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Christopher HowertonJefferies LLC
Roger SongJefferies LLC